Medpace
MEDP
$620.75
+1.32%
Medpace is a late-stage contract research organization (CRO) that provides full-service drug development and clinical trial management to small and mid-sized biotechnology, pharmaceutical, and medical device companies. The company differentiates itself through its therapeutic expertise, particularly in metabolic, oncology, and cardiovascular diseases, and its integrated approach that includes bioanalytical labs and imaging. Currently, the stock is in focus due to a strong rebound from an April earnings-driven selloff, with recent quarterly results showing robust revenue growth and margin expansion, while analysts debate the sustainability of its growth trajectory amid a competitive CRO landscape.…
MEDP
Medpace
$620.75
Related headlines
MEDP 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Medpace's 12-month outlook, with a consensus price target around $581.83 and implied upside of -6.3% versus the current price.
Average Target
$581.83
0 analysts
Implied Upside
-6.3%
vs. current price
Analyst Count
—
covering this stock
Price Range
$370 - $692
Analyst target range
The target price range spans from a low of $370.00 to a high of $692.00, with the high target implying a 11.5% upside and the low target implying a -40.4% downside. The wide spread of $322 suggests significant uncertainty about the company's future, possibly due to the volatile earnings history and competitive pressures. Recent ratings actions show a mix: Mizuho maintained Outperform, Baird downgraded from Outperform to Neutral, and Jefferies downgraded from Buy to Hold, indicating a shift toward caution. The high target likely assumes continued strong growth and margin expansion, while the low target may price in a slowdown in biotech funding or increased competition.
MEDP Technical Analysis
Medpace's stock has been in a strong uptrend over the past year, with a 1-year price change of +36.9%, significantly outperforming the S&P 500's +20.5% over the same period. The current price of $620.75 sits near the upper end of its 52-week range, at approximately 91.5% of the distance from the 52-week low of $373.0 to the high of $677.9. This positioning near highs suggests strong momentum, though it also raises the risk of overextension, especially after a sharp recovery from the April low.
Beta
1.15
1.15x market volatility
Max Drawdown
-36.6%
Largest decline past year
52-Week Range
$373-$678
Price range past year
Annual Return
+36.9%
Cumulative gain past year
| Period | MEDP Return | S&P 500 |
|---|---|---|
| 1m | +17.5% | +3.6% |
| 3m | +43.4% | +2.7% |
| 6m | +36.8% | +11.4% |
| 1y | +36.9% | +18.7% |
| ytd | +8.7% | +12.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MEDP Fundamental Analysis
Medpace's revenue trajectory has been robust, with Q1 2026 revenue of $706.6 million, up 26.5% year-over-year, and sequential growth from $708.5 million in Q4 2025, which was flat sequentially but up from $603.3 million in Q2 2025. The multi-quarter trend shows accelerating growth, with revenue rising from $558.6 million in Q1 2025 to $706.6 million in Q1 2026, a 26.5% increase. Revenue segments show metabolic (33.6% of total) and oncology (28.5%) as the largest drivers, with metabolic growing 26.5% year-over-year, while other segments like cardiology grew 18.5%.
Quarterly Revenue
$706604000.0B
2026-03
Revenue YoY Growth
+26.5%
YoY Comparison
Gross Margin
27.8%
Latest Quarter
Free Cash Flow
$737819000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MEDP Overvalued?
Given that Medpace is profitable with a trailing net income of $123.9 million, the primary valuation metric selected is the price-to-earnings (PE) ratio. The trailing PE is 35.9x, while the forward PE is 32.1x, implying the market expects earnings growth of about 12% over the next year. The gap between trailing and forward PE suggests modest growth expectations, which is consistent with the company's historical performance but may not fully reflect its recent acceleration.
PE
35.9x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 18x~40x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
28.0x
Enterprise Value Multiple